Targeting cancer with antibody-drug conjugates: Promises and challenges

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Poli...

Descripción completa

Detalles Bibliográficos
Autores principales: Dean, Alexis Q., Luo, Shen, Twomey, Julianne D., Zhang, Baolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300931/
https://www.ncbi.nlm.nih.gov/pubmed/34291723
http://dx.doi.org/10.1080/19420862.2021.1951427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8300931/
https://www.ncbi.nlm.nih.gov/pubmed/34291723
http://dx.doi.org/10.1080/19420862.2021.1951427

Ejemplares similares